Manthan Meeting-Transforming the Treatment Paradigm for patients with R/R Adult

Speciality: All Speciality


Speaker:

Dr Sameer Melinkeri | Head of Deaprtment & Director of Hematology and Bone Marrow Transplantation

Dr Akshay Shah | Consultant medico & Hemato Oncologist BMT Physician

Dr Varun Bafna | Hematologist & Hemato Oncologist Transplant Physician

Dr Ashok Rajoreya | Fellowship in Hemato-Oncology & Bone Marrow Transplantation

Dr Ankit Raiyani | Consultant Hematologist

Description:

A warm welcome to all the medical professionals in this interesting session on Manthan Meeting - Inotuzumab: Transforming the Treatment Paradigm for patients with R/R Adult B Cell ALL
The Manthan Meeting is a prominent conference that brings together leading hematologists, oncologists, and researchers to discuss transformative treatments for hematological malignancies. A key focus of the meeting is on the innovative use of Inotuzumab ozogamicin in the treatment of relapsed or refractory (R/R) adult B-cell acute lymphoblastic leukemia (ALL).
Inotuzumab ozogamicin is a groundbreaking antibody-drug conjugate that targets CD22, a surface antigen commonly expressed on B-cell ALL cells. By delivering a cytotoxic agent directly to the cancer cells, Inotuzumab offers a novel mechanism of action that has shown impressive efficacy in clinical trials, significantly improving remission rates for patients with R/R B-cell ALL.
Inotuzumab has changed this outlook by providing a potent, targeted therapy that offers new hope for achieving remission and extending survival in this challenging patient population.
Therefore, get an overall knowledge of update manthan meeting - inotuzumab: transforming the treatment paradigm for patients with R/R Adult B Cell ALL
 

See More Webinars @ Hidoc Webinars




Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Patients face high out-of-pocket costs after incident cancer diagnosis

2.

In a study, immune detection of oral cancers is linked to obesity.

3.

Researchers found that patients undergoing chemotherapy had a higher risk of mixed infections and should begin antibiotic therapy right away.

4.

Every cancer is different because of how evolution causes drug resistance and why various cancers require various treatments.

5.

Common intracellular toxin could help fight leukemia


© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot